Oxygen Double Bonded And Nitrogen Bonded Directly To The Same Carbon Patents (Class 536/53)
-
Publication number: 20100190728Abstract: Disclosed are analgesic-related compositions and methods of using the compositions for modulation of analgesic receptor activity. The compositions and methods are useful for reducing pain, as well as for therapeutic intervention of addictions or other diseases or disorders amenable to treatment or prophylaxis by modulation of analgesic receptor signaling.Type: ApplicationFiled: May 31, 2005Publication date: July 29, 2010Applicant: Human Biomolecular Research InstituteInventors: John R. Cashman, James M. MacDougall
-
Publication number: 20100184223Abstract: The present invention relates to a biomaterial for cell or tissue culture, based on a polymeric carrier, which contains at least one crosslinkable hydrophilic polymer. The polymer is functionalized with groups that are selected from maleimide, vinylsulfonic, acrylate, alkyl halide, azirine, pyridyl, thionitrobenzene acid groups, or arylating groups. The invention relates further to a method of production of said biomaterial, and the use of particular functionalizing groups for the production of a biomaterial for the cultivation of tissue and/or cells. The biomaterial can have biofactors that exert a particular action on cells.Type: ApplicationFiled: January 11, 2010Publication date: July 22, 2010Inventor: Helmut Wurst
-
Publication number: 20100184965Abstract: The invention relates to a complex consisted of a polysaccharide and an HBP, said polysaccharide being consisted from glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative. The invention also relates to a pharmaceutical composition comprising a complex according to the invention and to the use of a polysaccharide consisted of glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative, for the preparation of a pharmaceutical formulation of stable HBPs.Type: ApplicationFiled: September 28, 2009Publication date: July 22, 2010Applicant: ADOCIAInventors: Olivier Soula, Remi Soula, Martin Gaudier, Gerard Soula
-
Patent number: 7759323Abstract: The invention provides compositions containing a highly purified antiendotoxin compound and methods of preparing and using such compositions.Type: GrantFiled: May 22, 2002Date of Patent: July 20, 2010Assignee: Eisai R & D Management Co., Ltd.Inventor: John D. Orr
-
Publication number: 20100166695Abstract: Designed herein are multivalent heterobifunctional polymers for binding to a biological target exhibiting biological activity and to an effector template which can affect the biological activity of the biological target or detect the presence of the biological target. The polymers comprise a plurality of pre-arranged heterobifunctional ligands connected thereto, and each heterobifunctional ligand comprises a first functionality capable of binding to the biological target, and a second functionality capable of binding to the effector template. The heterobifunctional ligands are pre-arranged on the polymer so as to form a ternary complex between the polymer, the biological target and the effector template. The polymers, methods and compositions described herein provide an approach for the design and production of new therapeutic agents as well as agents useful in a variety of non-therapeutic applications.Type: ApplicationFiled: March 20, 2008Publication date: July 1, 2010Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTAInventors: David R. Bundle, Pavel kitov
-
Publication number: 20100152423Abstract: The disclosed is thiol-modified macromolecule derivatives having the general formula of (I) or (II), as well as the disulfide bond cross-linked materials and the thiol-reactive crosslinker cross-linked materials, wherein R1 and R2 are alkylene groups, substituted alkylene groups, aromatic groups or polyether groups and the like, respectively. R1 and R2 may have same or different chemical structure, and P is a residue of a macromolecule with side carboxyl group. The thiol-modified macromolecule derivative has a molecular weight of from 1000 to 5,000,000. The thiol-modified macromolecule derivative having the general formula of (I) or (II) of the present invention has a side chain with flexible chemical structure and adjustable properties, and has a number of advantages, such as mild reaction condition, high production yield, high degree of modifying, and the controllable modifying degree and so on.Type: ApplicationFiled: September 29, 2007Publication date: June 17, 2010Applicant: Bioregen Biomedical (Changzhou) Co., Ltd.Inventor: Chan Song
-
Publication number: 20100143300Abstract: The invention provides methods for treating hepatitis C viral infections and related viral infections, as well as compounds and compositions that are useful for treating such infections.Type: ApplicationFiled: March 6, 2009Publication date: June 10, 2010Inventors: Yarlagadda S. Babu, Pooran Chand, Minwan Wu, Pravin L. Kotian, V. Satish Kumar, Tsu-Hsing Lin, Yahya El-Kattan, Ajit K. Ghosh
-
Publication number: 20100137241Abstract: Biologically compatible polymers carry an imide and can be used as an adhesive, a hydrogel or both. A second biologically compatible polymer reactive with the imidated polymer can be used therewith to seal openings.Type: ApplicationFiled: December 4, 2007Publication date: June 3, 2010Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Jennifer H. Elisseeff, Iossif A. Strehin
-
Publication number: 20100137230Abstract: The present invention relates to compounds of the formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:Type: ApplicationFiled: January 29, 2010Publication date: June 3, 2010Inventor: Lutz Weber
-
Publication number: 20100117522Abstract: An organic material including a hydrophilic polymer and an organic moiety having a hydroxyl substituted C6-C14 aromatic functional group, the organic moiety binding to an end or a side of the hydrophilic polymer.Type: ApplicationFiled: June 2, 2009Publication date: May 13, 2010Applicants: SAMSUNG ELECTRONICS CO., LTD., KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Jong-jin PARK, Kwang-hee LEE, Xavier BULLIARD, Yun-hyuk CHOI, Tae-gwan PARK
-
Publication number: 20100099861Abstract: Provided is a complex obtained by reacting a polymer compound derivative obtained by modifying part of hydroxy groups or amino groups of a polymer compound having the hydroxy groups or amino groups with a compound represented by the following general formula (I) with one or more kinds of compounds represented by the following general formulae (II) to (V): (I) A-X—Si(Y)nR3-n (where A, X, Y, R, and n are as defined in claim 1) ; (II) M(OR1)nR24-n; (III) Al(OR1)pR23-p; (IV) Mg(OR1)gR22-q (where M, R1, R2, n, p, and q are as defined in claim 1); and (V) (where R3, R4, R5, and R6 are as defined in claim 1).Type: ApplicationFiled: May 2, 2008Publication date: April 22, 2010Inventors: Yoshio Okamoto, Chiyo Yamamoto, Tomoyuki Ikai, Masami Kamigaito
-
Patent number: 7700746Abstract: Material characterized by that the material contains at least one biologically active di- or trisaccharide or higher oligosaccharide which is covalently bound via a spacer to cross-linked agarose.Type: GrantFiled: December 23, 2003Date of Patent: April 20, 2010Assignee: Glycorex Transplantation ABInventor: Kurt Nilsson
-
Patent number: 7700747Abstract: A process for producing a polysaccharide sponge comprises the steps of (A) freezing a photoreactive polysaccharide solution, and (B) irradiating the frozen photoreactive polysaccharide solution with light to crosslink the photoreactive polysaccharide, thereby obtaining the polysaccharide sponge. The process includes simplified steps requiring no removal of solvent, and has such an advantage that impurities are easily removed therefrom.Type: GrantFiled: October 29, 2007Date of Patent: April 20, 2010Assignee: Seikagaku CorporationInventor: Tomoya Sato
-
Publication number: 20100093993Abstract: An object of the present invention is to provide a novel trehalose compound that exhibits excellent immunostimulating activity and that can be supplied in a large quantity in an industrial scale, and a method for producing the trehalose compound, wherein the trehalose compound of the present invention exhibits excellent immunostimulating activity, and is represented by general formula (1) below: wherein R1, R2, R3 and R4 may be the same or different, and independently represent a C10-16 alkyl group. The trehalose compound of the present invention is produced by removing a protective group (R5) for a hydroxyl group from a trehalose compound represented by general formula (5) below: wherein R1, R2, R3 and R4 are the same as above. R5 is a protective group for a hydroxyl group.Type: ApplicationFiled: January 30, 2008Publication date: April 15, 2010Applicant: OTSUKA CHEMICAL CO., LTD.Inventors: Mugio Nishizawa, Hiroshi Imagawa, Hirofumi Yamamoto, Jun Sakurai, Masataka Oda
-
Patent number: 7696177Abstract: This invention provides cholesterol absorption inhibitors of Formula (I), and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.Type: GrantFiled: June 9, 2006Date of Patent: April 13, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Robert J. DeVita, Greg J. Morriello, Anthony K. Ogawa, Feroze Ujjainwalla
-
Patent number: 7692000Abstract: A series of novel, melt- or mold-processable HA esters with varying aliphatic chain lengths are synthesized from silyl HA-quaternary (quat.) ammonium salt complex (preferably silyl HA-CTA, a silylated HA complex with cetyltrimethyl ammonium salt). Introduction of aliphatic acyl groups, preferably acid chlorides, to disrupt the strong HA intermolecular bonding, is done via acylation. Acylation takes place at the oxygen of the trimethylsilyloxy group —O—Si(CH3)3 in the silyl HA-CTA by removal of trimethylsilyl groups therefrom. Optionally, crosslinking may be performed during the shaping/molding of the HA esters into a structure/device, or thereafter, if at all. Native HA can then be regenerated/recovered by saponification hydrolysis, removing acyl groups, —CH3(CH2)10CO, and the cetyltrimethyl ammonium salt groups, -CTA, from HA ester. The structure/device of a preselected shape (e.g.Type: GrantFiled: September 20, 2004Date of Patent: April 6, 2010Assignee: Colorado State University Research FoundationInventors: Susan P. James, Min Zhang
-
Publication number: 20100075921Abstract: A process for preparing hyaluronic acid primarily as a food supplement which is capable of absorption and assimilation by the human body includes desirable control of both the purity and molecular weight range of the resulting product. Chicken comb tissue is subjected to one of two disclosed processes for extracting, purifying, and controlling the molecular weight range of hyaluronic acid in solution, which is then dried and powdered to a form suitable for human consumption as a food supplement. The resulting hyaluronic acid product can also be used topically in creams or solutions for beneficial treatment of skin conditions, such as dry skin or wrinkling, for example.Type: ApplicationFiled: November 25, 2009Publication date: March 25, 2010Inventor: Ahmad Alkayali
-
Patent number: 7683038Abstract: The present invention relates to percarboxylated polysaccharide selected from the group consisting of gellan, carboxymethylcellulose, pectic acid, pectin and hyaluronic acid derivatives; the process for their preparation and their use in the pharmaceutical, biomedical, surgical and healthcare fields.Type: GrantFiled: February 28, 2003Date of Patent: March 23, 2010Assignee: Fidia Farmaceutici S.p.A.Inventors: Davide Bellini, Vittorio Crescenzi, Andrea Francescangeli
-
Publication number: 20100069607Abstract: A glycopeptide of the formula S-L-X—P, wherein: S is selected from an optionally protected monosaccharide, an optionally protected polysaccharide, a polyalkylene oxide chain and a group of the formula II, wherein R1 and R3 are independently selected from H or Ac, R4 is Ac, and R2 is a group of formula IV, wherein R7 and R8 are each independently selected from an optionally protected monosaccharide and an optionally protected polysaccharide, A, B, C and D are each independently 1 or 2, and m is 1 to 5; -L- is a moiety of the formula III wherein R5 and R6 are independently selected from H and Me and n is 1 to 3; and P is a peptide chain containing at least one amino acid having on its side chain the atom X, wherein X is an oxygen, a sulphur atom or a —CH2— moiety.Type: ApplicationFiled: June 29, 2007Publication date: March 18, 2010Applicant: UCL BUSINESS PLCInventors: Derek MacMillan, Javier Blanc
-
Publication number: 20100063001Abstract: Described is chondroitin sulfate obtained from microbial sources, and related compositions and methods.Type: ApplicationFiled: June 3, 2009Publication date: March 11, 2010Inventors: James F. Jolly, Krzysztof Klimaszewski, Yuuji Nakanishi, Hirotaka Matsubara, Tetsuya Takahashi, Kyouichi Nishio
-
Patent number: 7667012Abstract: The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g. on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).Type: GrantFiled: April 20, 2006Date of Patent: February 23, 2010Assignee: The Regents of the University of CaliforniaInventors: Eliana Saxon, Carolyn R. Bertozzi
-
Patent number: 7662953Abstract: The invention relates to a method for manufacturing cellulose carbamate. In the method, an auxiliary agent and urea in solution form and possibly in solid form are absorbed into cellulose, and a reaction between cellulose and urea is carried out in a mixture containing cellulose, a liquid, the auxiliary agent, and urea The absorption of the auxiliary agent and urea into cellulose, and the reaction between the cellulose and the auxiliary agent at least partly are carried out in a working device. According to the invention, it is possible to manufacture cellulose carbamate without ammonia, organic solvents or other auxiliary agents, by using only a small quantity of water as a medium.Type: GrantFiled: January 29, 2003Date of Patent: February 16, 2010Assignee: Valtion Teknillinen TutkimuskeskusInventors: Kyösti Valta, Eino Sivonen
-
Publication number: 20100028431Abstract: A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.Type: ApplicationFiled: April 13, 2009Publication date: February 4, 2010Applicants: Canji Inc.,, Schering Corporation,Inventors: Heidrun Engler, Tattanahalli L. Nagabhushan, Stephen Kenneth Youngster
-
Patent number: 7645873Abstract: This invention relates to galactosylceramide compounds.Type: GrantFiled: March 20, 2003Date of Patent: January 12, 2010Assignees: The Scripps Research Institute, Brighman Young University, The University of ChicagoInventors: Paul B. Savage, Albert Bendelac, Luc Teyton
-
Publication number: 20100004184Abstract: This invention provides cholesterol absorption inhibitors of Formula (I), and the pharmaceutically acceptable salts and esters thereof. The compounds arc useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.Type: ApplicationFiled: June 9, 2006Publication date: January 7, 2010Inventors: Robert J De Vita, Greg J. Morriello, Anthony K. Ogawa, Feroze Ujjainwalla
-
Publication number: 20090326215Abstract: Glucopyranosyl-substituted benzene derivatives of general formula I where the groups R1 to R6 as well as R7a, R7b, R7c are defined herein and the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.Type: ApplicationFiled: August 21, 2009Publication date: December 31, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Matthias ECKHARDT, Peter EICKELMANN, Frank HIMMELSBACH, Edward Leon BARSOUMIAN, Leo THOMAS
-
Publication number: 20090318678Abstract: The invention concerns a C-glycoside compound of formula (I); wherein: n is equal to 1 or 2; Y represents H or halogen; X is an alkyl chain bearing at least one amino, amide, acid, ester, carbonyl, alcohol, aryl function or a carbonyl, ester amide, amino, alcohol group; the R's, identical or different, represent a OH or OR? group where R? is an alkyl, benzyl, benzoyl, acetyl, pivaloyl, trialkylsilyl, tertiobutyldiphenylsilyl group or one or more sugars; R1 represents OR?, NR?R??, N3, or a phthalamide with R? and R??, identical or different, represent H or an alkyl, aryl, benzyl, benzoyl, acetyl, alkoxycarbonyl, allyloxycarbonyl, benzyloxycarbonyl group; R2 represents H or halogen or a OH, OR, NR?R?? or N3 group, as well as derivatives thereof in physiologically or pharmaceutically acceptable base, mineral or organic acid-addition salt, hydrate or solvate form.Type: ApplicationFiled: April 23, 2007Publication date: December 24, 2009Applicant: TFCHEMInventors: Géraldine Castelot-Deliencourt-Godefroy, Jean-Charles Quirion, Philippe Jubault, Ludivine Zoute
-
Publication number: 20090269407Abstract: The present invention provides biocompatible, biodegradable matrices formed from poly-?(1?4)glucopyranose and reactive hydrazide groups. The matrices can be used for various applications in the body, including drug delivery and cell therapy.Type: ApplicationFiled: April 27, 2009Publication date: October 29, 2009Inventors: Emily R. Rolfes, Jeff J. Ross, Joseph S. McGonigle, Gary W. Opperman, Stephen J. Chudzik, Pamela J. Reed
-
Patent number: 7605242Abstract: The invention relates to a process for the depolymerization of glycosaminoglycanes characterized by the use of UVC radiation. The invention also relates to the intermediate depolymerized heparin obtained by the process. The intermediate depolymerized heparin can be dissolved in a buffer solution and fractionated by gel permeation for obtaining the desired molecular weight.Type: GrantFiled: May 6, 2004Date of Patent: October 20, 2009Assignee: Laboratori Derivati Organici S.p.A.Inventors: Luigi De Ambrosi, Donata Bensi, Elena Vismara
-
Patent number: 7601704Abstract: A method for synthesizing uniformly sized hyaluronic acid (“HA”) particles that are substantially free from oil and surfactant contaminants. The method comprises crosslinking HA chains with 1-ethyl-3-(3-dimethlyaminopropyl) carbodiimide hydrochloride (“EDAC”) and adipic acid dihydrazide in a water/acetone mixture.Type: GrantFiled: November 3, 2004Date of Patent: October 13, 2009Assignee: University of North TexasInventors: Zhibing Hu, Xiaohu Xia, Liping Tang
-
Publication number: 20090252810Abstract: The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties that can be used for advanced formulation (bind stronger to the skin compared to non-modified HA), possibly also in delivery systems for actives or drugs by encapsulation (nano/micro capsules) or formation of nano/micro spheres. Further, the low MW ASA-HA derivatives are expected to penetrate the skin more efficiently than non-modified HA of the same MW.Type: ApplicationFiled: September 26, 2006Publication date: October 8, 2009Applicant: NOVOZYMES BIOPOLYMER A/SInventors: Kristoffer Tommeraas, Corinne Eenschooten
-
Patent number: 7598354Abstract: Multiple strains and species of Campylobacter share a common glycan moiety which is present in a plurality of surface-exposed glycoproteins. This glycan has the formula: GalNAc-a1, 4-GalNAc-a1,4-[Glc-?1,3]GalNAc-a1,4-GalNAc-a1,4-GalNAc-a1,3-Bac, wherein Bac is 2, 4-diacetamido-2,4,6-trideoxy-D-glucopyranose. This glycan and immunologically active fragments of it have use as vaccines against campylobacter infection in humans and animals. As well, antibodies which specifically bind these compounds may be provided. Such antibodies and vaccines may be used to prevent or neutralize campylobacter infections in livestock thereby preventing this pathogen from entering the human food chain. The glycan may be linked to one or more amino acids to form a glycopeptide. As well, a method for determining the glycan structure of an intact glycoprotein consists of subjecting a sample to high resolution magic angle spinning nuclear magnetic resonance (HR-MAS-NMR) spectroscopy.Type: GrantFiled: July 30, 2003Date of Patent: October 6, 2009Assignee: National Research Council of CanadaInventors: Noel M. Young, Jean-Robert Brisson, John Francis Kelly, David C. Watson, Harold C. Jarrell, Christine M. Szymanski
-
Publication number: 20090227524Abstract: The invention provides compounds of Formula I: as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of Formula (I) are useful as anti-viral agents and/or as anti-cancer agents.Type: ApplicationFiled: March 5, 2009Publication date: September 10, 2009Applicant: BioCryst Pharmaceuticals, Inc.Inventors: Yarlagadda S. Babu, Pooran Chand, Pravin Kotian, Minwan Wu, V. Satish Kumar
-
Publication number: 20090227781Abstract: Glycolipid derivatives having the formula (I): wherein R1 indicates an aldopyranose residue, R2 indicates a hydrogen atom or hydroxyl group, A indicates —CH2—, —CH(OH)—CH2— or —CH?CHCH2—, Z indicates —O— or —CH2—, when Z is —O— and x is an integer of 4 to 16, y indicates an integer of 26 to 35, when Z is —O— and x indicates an integer of 17 to 25, y indicates an integer of 0 to 35, when Z is —CH2— and x indicates an integer of 4 to 15, y indicates an integer of 26 to 35, and when Z is —CH2— and x indicates an integer of 16 to 25, y indicates an integer of 0 to 35 and a drug containing the glycolipid derivative for treatment of autoimmune arthritis and other autoimmune disease, bronchial asthma and other allergic diseases or diseases in which NKT cells or stimulation of NKT cells is known to be participating in the deterioration of conditions.Type: ApplicationFiled: June 30, 2006Publication date: September 10, 2009Inventors: Sachiko Miyake, Takashi Yamamura, Tetsuya Toba
-
Publication number: 20090187013Abstract: Preparation of synthetic monosaccharides, disaccharides, trisaccharides, tetrasaccharides and pentasaccharides for use in the preparation of synthetic heparinoids.Type: ApplicationFiled: January 15, 2009Publication date: July 23, 2009Applicant: Alchemia LimitedInventors: Joachim SEIFERT, Latika Singh, Tracie Elizabeth Ramsdale, Michael Leo West, Nicholas Barry Drinnan
-
Patent number: 7553981Abstract: The subject of the present invention is new substances which are derived from naturally occurring ceramides and sphingosine and also from synthetic compounds with principally the same structure in that they represent dimers, trimers, tetramers etc., hence i.e. oligomers of the initial substances.Type: GrantFiled: June 4, 2004Date of Patent: June 30, 2009Assignee: PLT Patent and License Trading Ltd.Inventors: Hans Uwe Wolf, Jörg Martin Dormann
-
Publication number: 20090155862Abstract: A process for the preparation of 2-hydroxymethyl-pyrrolidine-3,4-diols of the formulae: including the steps of: a) bioxidation of N-protected aminotetraols of the formula: b) deprotection of the corresponding 5-amino-5-deoxy-pentulose of the formula: and c) hydrogenation of the corresponding 5-amino-5-deoxy-pentulose of the formula:Type: ApplicationFiled: February 18, 2009Publication date: June 18, 2009Inventors: Ulrich KAMPFEN, Eva Maria URBAN, Claus JESSEN, Martin CLAUSEN
-
Publication number: 20090148534Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction rate of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction rate as that of the conventionally known gel.Type: ApplicationFiled: September 7, 2005Publication date: June 11, 2009Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Kenji Yasugi, Teruo Nakamura, Tsuyoshi Shimoboji, Mika Sato
-
Publication number: 20090118201Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.Type: ApplicationFiled: August 22, 2008Publication date: May 7, 2009Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael J. Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Y. Roberge
-
Patent number: 7510657Abstract: The present invention is a method of preparing affinity ligands, which method comprises to provide a cyclic scaffold comprising a thiol group, a carbonyl group and an amine group; to derivatize the amine group of said scaffold with an electrophile that carries either a functionality capable of affinity interaction or a functionality capable of a second interaction with a target molecule; and to open up the derivatized scaffold and add an amine that carries either a functionality capable of a second interaction or a functionality capable of affinity interaction with a target molecule. The method provides provide affinity ligands, which are capable of affinity interaction as well as a second kind of interaction.Type: GrantFiled: March 5, 2004Date of Patent: March 31, 2009Assignee: GE Healthcare Bio-Sciences ABInventors: Jean-Luc Maloisel, Nicolas Thevenin
-
Patent number: 7507723Abstract: Hyaluronic acid oligosaccharides having a size selected from sizes of 4 to 60 saccharides, fractions containing the hyaluronic acid oligosaccharides and having particular physicochemical properties, and drugs containing the same. The hyaluronic acid oligosaccharides of the present invention are extremely useful, because they exert superior pharmaceutical effects as active ingredients of a heat shock protein expression promoter, cell death inhibitor, cell injury inhibitor and cell and tissue protecting agent (e.g., organ preservation agent, antiulcer agent, antihepatopathic agent, IL-10 production promoter or IL-8 production inhibitor) and exhibit high safety.Type: GrantFiled: July 6, 2001Date of Patent: March 24, 2009Assignee: Seikagaku CorporationInventors: Akira Asari, Hitoshi Kurihara, Tomomi Shibata, Yuka Miyazaki, Hiroko Yamanokuchi, Akira Tawada, Takahiro Masa, Yuji Matsuzaki
-
Publication number: 20090076257Abstract: The present invention relates to hyaluronic acid ester derivatives, whose carboxylic groups are partially esterified with hydroxy groups of propiophenone derivatives, to the hydrogel materials consisting of the said hyaluronic acid ester derivatives, to their preparation process by photocuring of the hyaluronic acid ester derivatives, and their use in the biomedical, sanitary and surgical fields, and in the medical field as controlled release systems for drugs.Type: ApplicationFiled: October 7, 2008Publication date: March 19, 2009Applicant: Fidia Farmaceutici S.p.A.Inventors: Davide Bellini, Anna Maria Zanellato
-
Publication number: 20090042811Abstract: The syntheses and in vitro antitumor properties of carbamate-containing, dicarbamate-containing, and ureido-containing phospholipid compounds that have an ether linkage at the C-1 position of a glycerol backbone, a carbamate, dicarbamate, or ureido moiety at the C-2 position of the glycerol backbone, and a phosphocholine, phosphonocholine, or glycoside moiety at the C-3 position of the glycerol backbone are described. The synthesis and antiproliferative activity of ether lipids with a naphthol moiety at the C-1 position are also described. These compounds were shown to be potent inhibitors of cancer cell growth. These compounds are useful for killing cancer cells and treating cancer.Type: ApplicationFiled: June 12, 2006Publication date: February 12, 2009Inventors: Robert Bittman, Hoe-Sup Byun, Gilbert Arthur
-
Patent number: 7485718Abstract: A process for the synthesis of beta linked low molecular weight polymers of galactosamine and glucosamine has been developed. Through the use of high amounts of activating agents, efficient coupling of stable monomers is achieved. Using this process, chain extension is through the addition of single monomers, providing populations of single chain length polyhexosamines.Type: GrantFiled: June 16, 2005Date of Patent: February 3, 2009Assignee: E. I. du Pont de Nemours and CompanyInventor: Subramaniam Sabesan
-
Publication number: 20090029006Abstract: A novel compound causing an oral cavity stimulus such as acridness, which is expressed by the following structural formula (I):Type: ApplicationFiled: November 29, 2005Publication date: January 29, 2009Inventors: Norihiko Kageyama, Takako Inui, Koichi Nakahara, Hajime Komura
-
Publication number: 20090005321Abstract: Various azetidinone derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.Type: ApplicationFiled: February 9, 2006Publication date: January 1, 2009Applicant: Microbia, Inc.Inventors: Daniel P. Zimmer, John Jeffrey Talley, Regina Lundrigan, Shannon Roberts, Eduardo J. Martinez
-
Publication number: 20090005542Abstract: The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.Type: ApplicationFiled: June 25, 2008Publication date: January 1, 2009Applicants: Baxter International Inc., Baxter Healthcare SAInventors: Peter Turecek, Juergen Siekmann
-
Publication number: 20080300220Abstract: Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLeX compositions. In particular, the disclosed SLeX compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLeX compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl LeX, and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.Type: ApplicationFiled: August 13, 2008Publication date: December 4, 2008Applicant: BRACCO INTERNATIONAL B.V.Inventors: Ramachandran Ranganathan, Kondareddiar Ramalingam, Radhakrishna Pillai, Edmund R. Marinelli, Rolf E. Swenson
-
Patent number: 7459579Abstract: An optically active dihydroxyheptenoic acid ester having an aromatic group is separated from a solution containing a mixture of optical isomers of digydroxyheptenoic acid ester by liquid chromatography with a packing material constituted of a carrier and a polysaccharide derivative carried on the carrier. The polysaccharide derivative is a polysaccharide in which the hydrogen atoms constituting the hydroxyl and amino groups are partially or all replaced by one or more kinds of groups selected from among carbamoyl groups monosubstituted with aromatic groups having specific alkyl groups and benzoyl groups having specific alkyl groups. According to the invention, optically active dihydroxyheptenoic acid esters can be separated more distinctly.Type: GrantFiled: October 21, 2005Date of Patent: December 2, 2008Assignee: Daicel Chemical Industries, Ltd.Inventors: Keiko Kudo, Kozo Tachibana, Koichi Murazumi
-
Publication number: 20080280836Abstract: This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R12 is an alkyl, alkeny or alkynyl group mono- or poly-substituted with —OH, —COOH or a combination of —OH and —COOH, and R9 contains an alkyl, alkeny or alkynyl group substituted with a heterocyclic ring, amino or sulfonyl. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.Type: ApplicationFiled: May 8, 2008Publication date: November 13, 2008Inventors: Gregori J. Morriello, Robert J. DeVita